A carregar...
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
BACKGROUND: Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive response rates and durable disease remission...
Na minha lista:
| Publicado no: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6336005/ https://ncbi.nlm.nih.gov/pubmed/30395155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy495 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|